Julius-Maximilians University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Wurzburg Germany (1402)

Organization Overview

First Clinical Trial
2000
NCT00157378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chairman Dept. of Periodontology, University Hospital Wuerzburg, Germany | Children's Hospital, University Medical Center Göttingen | Department of Dermatology, University of Wuerzburg, Germany | Department of Internal Medicine, University of Wuerzburg, Germany | Department of trauma, hand, reconstructive and plastic, University of Wuerzburg | Dept of Dermatology, University of Wuerzburg | Dept. of Internal Medicine II, University of Wuerzburg | Dept. of Internal Medicine II, University of Wuerzburg, Klinikstr. 6-8, 97070 Wuerzburg | Dept. of Internal Medicine, University of Wuerzburg | Universitaets-Hautklinik Wuerzburg | Universitaets - Kinderklinik Wuerzburg | Universitätsklinikums Würzburg | University Hospital Wuerzburg | University Hospital Wuerzburg- Departement of Medicine II | University Hospital Wuerzburg, Germany | University of Würzburg | University of Wuerzburg | University of Wuerzburg. Department of Endocrinology | University of Wuerzburg Medical Centre, Department of Internal Medicine II | Würzburg University Hospitals | Wuerzburg University | Wuerzburg University Hospital | Wuerzburg University Hospital, Dept. of Hematology and Oncology | Wuerzburg University Hospital, Dept. of Internal Medicine II

Active Ingredients

Drugs in Phase 4 Trials (6)

haloperidol (haldol) (2 trials)

hydroxyethyl starch (voluven) (1 trial)

lorazepam (ativan) (1 trial)

pegvisomant (somavert) (1 trial)

ringer's lactate (1 trial)

risperidone (risperdal) (1 trial)

Drugs in Phase 3 Trials (24)

allogeneic adipose derived mesenchymal stem cell (1 trial)

allogeneic stem cells (2 trials)

apixaban (eliquis) (1 trial)

autologous mononuclear stem cell (1 trial)

bone marrow derived mononuclear cells (1 trial)

bortezomib (velcade) (3 trials)

burosumab-twza (crysvita) (1 trial)

carfilzomib (kyprolis) (1 trial)

cisplatin (platinol) (2 trials)

cytarabine (cytosar-u) (1 trial)

dabigatran (pradaxa) (1 trial)

dacarbazine (dtic-dome) (2 trials)

dexamethasone (1 trial)

edoxaban (savaysa) (1 trial)

elotuzumab (empliciti) (1 trial)

lenalidomide (revlimid) (4 trials)

methylphenidate (ritalin) (1 trial)

mitotane (lysodren) (1 trial)

paclitaxel (taxol) (1 trial)

rivaroxaban (xarelto) (1 trial)

temozolomide (temodar) (1 trial)

treosulfan (1 trial)

tumor-pulsed dendritic cells (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (20)

123i-iodometomidate (1 trial)

allogeneic b-lymphocytes (1 trial)

allogeneic central memory t cells (1 trial)

autologous dendritic cells loaded with autologous tumor lysate (1 trial)

blinatumomab (blincyto) (1 trial)

cabozantinib (cometriq) (1 trial)

caspofungin (cancidas) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

dimethyl fumarate (tecfidera) (1 trial)

doxorubicin (Doxil) (1 trial)

mirtazapine (remeron) (1 trial)

nimotuzumab (2 trials)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (1 trial)

slamf7 car-t (1 trial)

spironolactone (aldactone) (1 trial)

sunitinib (sutent) (1 trial)

survivin peptide vaccine (1 trial)

urea (3 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (4)

fludarabine (fludara) (1 trial)

lilotomab (1 trial)

unicar02-t (1 trial)

unicar02-t-ppsma (1 trial)

Drugs in Other Trials (18)

125-iodine (1 trial)

azelastine (astelin) (1 trial)

carboplatin (paraplatin) (1 trial)

collagen (1 trial)

corticotropin (acthar) (1 trial)

dark chocolate (1 trial)

etoposide (vepesid) (1 trial)

fluticasone (cutivate) (1 trial)

i-124 (1 trial)

lactobacillus reuteri (1 trial)

ledipasvir (Harvoni) (1 trial)

lomustine (1 trial)

naltrexone (revia) (1 trial)

ribavirin (virazole) (1 trial)

sofosbuvir (sovaldi) (1 trial)

tetranitropentaerythritol (1 trial)

thiotepa (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Acromegaly (Phase 4)

Addison Disease (Phase 2)

Adrenal Gland Neoplasms (Phase 2)

Adrenal Insufficiency (Phase 2)

Adrenocortical Carcinoma (Phase 3)

Anemia, Aplastic (Phase 2)

Atrial Fibrillation (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Carcinoma (Phase 3)

Cerebral Hemorrhage (Phase 3)

Disease Progression (Phase 2)

Edema (Phase 3)

Familial Hypophosphatemic Rickets (Phase 3)

Fibromyalgia (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Heart Failure (Phase 4)

Hemorrhage (Phase 3)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 2)

Hypertrophy (Phase 4)

Hypertrophy, Left Ventricular (Phase 4)

Hypophosphatemia (Phase 3)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 3)

Multiple Myeloma (Phase 3)

Mycoses (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myofascial Pain Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Schizophrenia (Phase 4)

Sepsis (Phase 4)

Syndrome (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uveal Neoplasms (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 50
  • # of Trial APIs: 72